BIOMEDICA MOLECULAR MEDICINE. XII Foro de Inversin madri+d
BMM una iniciativa del Hospital Universitario La Paz, dedicada al desarrollo, implementacin y comercializacin de herramientas moleculares que ayuden a los ...
By: madri+d emprendedores
Visit link:
BIOMEDICA MOLECULAR MEDICINE. XII Foro de Inversin madri+d - Video
New York, NY (PRWEB) February 12, 2014
Kalorama Information has published Molecular Diagnostics Six Month Update, the latest look at this fast-growing IVD test segment.
Molecular diagnostics is becoming a dominant platform in clinical medicine and represents one of the fastest growing segments of the diagnostics market. In light of the amount of activity in test development and regulatory and reimbursement challenges in 2013, Kalorama Information presents this updated review of molecular diagnostics with an emphasis on the last six months of 2013: July December. This report highlights trends and developments that portent the evolution of molecular tests and technologies. The ensemble of consumer demand, technological advances and market forces create a dynamic, energetic and fast-moving environment for new tests and companies.
Though focused on the developments of the last six months, coverage is substantial. As part of its coverage, this report provides, current market size and forecasts for Molecular Diagnostic Segments, including:
The report provides breakout of key market segments for molecular diagnostic markets in world regions, including developed nations and emerging nations. In addition the following important trend information is also provided:
Market analysis in this report covers world markets for in vitro diagnostics, however the reader will find a bias toward the developed areas of the globe -- North America and Western Europe. However public health and infectious disease are a growing global problem and where possible the report covers IVD products related to the globalization of diseases. The information presented in this report is derived primarily from company reports and other publicly available information published by government, and medical organizations.
The Molecular Diagnostics Six Month Update is available at http://www.kaloramainformation.com/Molecular-Diagnostics-Month-7969379/.
About Kalorama Information Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog.
Read more:
Kalorama Information Publishes Molecular Diagnostics Market Update
Frisco, Texas (PRWEB) February 12, 2014
ION Solutions, a diversified physician services organization whose membership represents more than half of the private practice oncologists in the United States, today announced the selection of Foundation Medicine as its preferred partner for comprehensive cancer genomic profiling services. Foundation Medicines clinical products, FoundationOneTM for solid tumors and FoundationOneTM Heme for hematologic malignancies, sarcomas and pediatric cancers, each provide a fully informative genomic profile that complement traditional cancer treatment decision tools and often expands treatment options by matching each patient with targeted therapies that are relevant to the molecular changes in their tumor. This relationship will advance the organizations shared goals of providing comprehensive cancer diagnostic tools to community oncologists and their patients.
Foundation Medicine is the leader in providing comprehensive genomic profiling to the broad oncology community, said Barry Fortner, President, ION Solutions. We look forward to our preferred partnership to provide these important tools to community oncologists to help inform treatment decisions and enable precision medicine for their patients.
ION Solutions is known for bringing cutting edge technologies to its vast network of community oncologists, and we are very pleased to have been selected as their preferred comprehensive genomic profiling services partner, commented Kevin Krenitsky, M.D., chief commercial officer and senior vice president, international strategy, Foundation Medicine. Our mission at Foundation Medicine is to provide broad access to clinical grade and comprehensive genomic sequencing to oncologists at both academic medical centers and community practices, and we believe this partnership will help further these efforts.
Foundation Medicine has developed the first commercially available targeted sequencing assays using comprehensive, clinical next-generation sequencing to assess routine cancer specimens for all genes that are currently known to be somatically altered and unambiguous drivers of oncogenesis in solid tumors and hematologic malignancies, as well as many sarcomas and pediatric cancers. Genomic profile results are reported to the oncologist and matched with targeted therapies and clinical trials that may be relevant to each individual patient based on the most recent scientific and medical research. For more information or to order Foundation One and FoundationOne Heme, please visit http://www.FoundationOne.com.
About ION Solutions and AmerisourceBergen ION Solutions, a part of AmerisourceBergen Specialty Group, is the largest physician service organization and GPO specializing in the support of community oncology. ION provides technologies, resources and expertise to community-based oncologists to help improve clinical and operational management. Additional information can be found at http://www.iononline.com. AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel. With over $100 billion in annualized revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs approximately 13,000 people. AmerisourceBergen is ranked #32 on the Fortune 500 list. For more information, go to http://www.amerisourcebergen.com.
About Foundation Medicine Foundation Medicine (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patients unique cancer. The companys clinical assays, FoundationOneTM for solid tumors and FoundationOneTM Heme for hematologic malignancies, sarcomas and pediatric cancers, each provide a fully informative genomic profile to identify a patients individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicines molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine is a registered trademark, and FoundationOneTM is a trademark, of Foundation Medicine, Inc.
See the original post:
Introduction: Checkpoint Inhibition in Non-Small Cell Lung Cancer
Moderator Corey J. Langer, MD, introduces a panel discussion focused on frontline treatment approaches and evolving maintenance strategies for patients with ...
By: OncLiveTV
Read more from the original source:
Introduction: Checkpoint Inhibition in Non-Small Cell Lung Cancer - Video
02/03/2014 | 04:20pm US/Eastern
PRESS RELEASE
MolMed provides an update on the registration strategy for its gene therapy TK in Europe and in the United States
Milan (Italy), 3 February 2014 - MolMed S.p.A. (Milan:MLM) today provided an update on the registration strategy for its gene therapy TK in Europe and in the US.
With regard to the Conditional Approval procedure in EU, after two meetings with the national agencies from rapporteur and co-rapporteur member states designated by the European Medicines Agency (EMA), the Company confirms the expected filing date of the application in the first quarter of 2014. As far as the Breakthrough Therapy submission is concerned, the U.S. Food and Drug Administration (FDA) has not - at this time - granted the designation for the cell therapy TK as adjunctive treatment in hematopoietic stem cell transplantation (HSCT) for adult patients affected by high risk acute leukaemia. However, the FDA indicates that the Company can submit a new request once new clinical evidence becomes available. According to this suggestion, MolMed intends to re-apply for Breakthrough Therapy designation in the US since new evidence is now becoming available, including initial efficacy data from the ongoing Phase III clinical trial. These data will be submitted for presentation at next meeting of the American Society of Clinical Oncology (ASCO).
About Breakthrough Therapy
Breakthrough Therapy designation is a new regulatory option available at FDA and is intended to expedite the development and review of drugs for serious or life-threatening conditions. The criteria for breakthrough therapy designation require preliminary clinical evidence that demonstrates the drug may have substantial improvement on at least one clinically significant endpoint over available therapy. A breakthrough therapy designation conveys all of the fast track program features as well as more intensive FDA guidance on an efficient drug development program. Details of these regulatory processes can be found at this link: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantA mendmentstotheFDCAct/FDASIA/ucm341027.htm The last update provided by the FDA on Dec 31st 2013 shows that only 2 requests have been granted out of the 22 submitted.
About TK
TK is a cell therapy product, based on the use of genetically engineered donor T cells carrying a "suicide gene". These cells are administered to patients during the haematopoietic stem cell transplantation for the treatment of high risk leukaemia. TK therapy allows to eliminate the post-transplant immunosuppression treatment thus accelerating the immune reconstitution and controlling the immunological consequences arising from the genetic differences with the donor, known as Graft versus Host Disease (GvHD).
About Phase III trial TK008
View original post here:
CING-CSMM Herb Garden
We are sure you know the benefits of living in a green environment. This is not always possible however especially in urban city centre locations. At the Cyp...
By: Cyprus Institute of Neurology and Genetics
Read more:
PUBLIC RELEASE DATE:
30-Jan-2014
Contact: Karen Kreeger karen.kreeger@uphs.upenn.edu 215-349-5658 University of Pennsylvania School of Medicine
PHILADELPHIA Substances called adjuvants that enhance the body's immune response are critical to getting the most out of vaccines. These boosters stimulate the regular production of antibodies -- caused by foreign substances in the body -- toxins, bacteria, foreign blood cells, and the cells of transplanted organs.
But, biologists think that vaccine adjuvants could be much better: The currently available licensed adjuvants are poor inducers of T helper cells and even worse at inciting killer T cells that clear viruses, as well as eradicate cancer cells.
The lab of David Weiner, PhD, professor of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, identifies new adjuvants that can produce the desired T-cell response. "Different molecular adjuvants, such as cytokines, are being studied as a way to increase the efficacy of vaccines," explains Weiner. "The development of DNA-based vaccines with cytokine adjuvants has emerged as particularly promising for inducing antiviral and anti-tumor, cell-mediated immune responses."
Daniel Villarreal, a graduate student in the Weiner lab, and colleagues report in Cancer Research this week that the protein IL-33 boosts the immune system of a human papilloma virus animal model of cancer. IL-33 is a cytokine, a small protein that signals immune cells such as T cells to travel to a site of infection or injury.
Although still experimental, DNA vaccines are a conceptual leap forward over standard vaccines, as they are not live and never expose the person being vaccinated to a true pathogen or infectious agent. They are transient and do their job by fooling the host's immune system into believing there is an infectious agent invading their cells so that the host responds by producing protective levels of T cells, in particular CD8 killer T cells. DNA vaccines have been studied in animal models of viral, bacterial, and parasitic disease, as well as animal models of tumors. Due to major advances in their immune potency DNA vaccines are being studied in human clinical trials for treating cancer and infectious diseases.
The team showed that IL-33 can further enhance the response of memory T cells, the long-lived cells that can patrol and protect the body from infections and cancers, when given with a DNA vaccine compared to a vaccine without IL-33. What's more, IL-33 and the DNA vaccine augmented immunological responses in both CD4 helper T cells and CD8 killer T cells, with a large proportion of CD8 killer T cells demonstrating a further improvement in the ability of DNA vaccines to drive the immune system to kill tumor cells in animals.
"Our results support the further study and possible development of IL-33 as adjuvants in vaccinations against pathogens, including in the context of antitumor immunotherapy," says Weiner. Additional cancer and infectious diseases studies in diverse animal models are in progress.
Continued here:
Protein serves as a natural boost for immune system fight against tumors
The biochemist Professor Volker A. Erdmann at Freie Universitt Berlin succeeded for the first time in creating mirror-image enzymes -- so-called Spiegelzymes -- out of nucleic acids. The Spiegelzymes can be used in living cells for the targeted cutting of natural nucleic acids.
In an article published in PLOS ONE, Erdmann and his co-authors delineate how engineered Spiegelzymes have great potential for cutting up individual nucleic acids responsible for human diseases, and thus "deactivating" them. According to Erdmann Spiegelzymes, also called molecular scissors, have the advantage that they do not trigger side reactions of the immune system and they are extremely stable.
In the experiments Erdmann and his team were able to show that with specially constructed Spiegelzymes the production of a green glowing protein could be inhibited in the cells. The Spiegelzymes cut the messenger RNA, the molecule responsible for the production of the protein. Following similar procedures, it should be possible to prevent the synthesis of any one of the approximately 21,000 proteins anchored in the human genome, says Erdmann.
Volker A. Erdmann thinks it is plausible that in the future it will be possible to intervene in the processes of a cell to selectively cut RNA molecules that regulate the synthesis of proteins and other nucleic acids. Since RNA molecules are responsible for ensuring that a stem cell develops into a skin cell or muscle cell, or even a tumor cell, the targeted use of Spiegelzymes shows promise for completely new applications in basic research, biotechnology, and molecular medicine.
Story Source:
The above story is based on materials provided by Freie Universitaet Berlin. Note: Materials may be edited for content and length.
Read more:
Mirror-image nucleic acids as molecular scissors in biotechnology and molecular medicine
It was an encounter with a little girl who suffered from an enigmatic neurological disorder that set molecular geneticist Huda Zoghbi on a journey of unexpected scientific discovery, taking her from the paediatric clinic to a medical laboratory, where she would unravel the genetic origins of a rare and devastating condition Rett Syndrome.
Professor Zoghbi, now Professor of Paediatrics, Neurology, Molecular and Human Genetics and Neuroscience at the Baylor College of Medicine, spoke on Monday of the significance of her days as a clinician when she was able to catch medical clues to the relatively unknown disease, and the promise of a treatment made possible by genome sequencing, which can today help identify the cause of several disorders.
It was 16 years after she met her first patient at the Texas Medical Centre in 1983 that she discovered a genetic mutation linked to Rett Syndrome, which caused a critical reduction of the methyl-CpG-binding protein 2 (MECP2) and affected every part and every function of the brain, Professor Zoghbi said in a lecture A journey from the clinic to the laboratory to understand brain disorders she delivered as part of the Cell Press-TNQ India Distinguished Lectureship Series.
Rett Syndrome, an autism spectrum disorder that primarily affects girls (1 in 10,000), alters no fewer than 2,500 genes, causing learning and memory deficits, motor dysfunction and sometimes convulsions. And curiously, this hereditary condition sets in six to 18 months into the childs life: The girl who would sing along to nursery rhymes and greet her father when he returned from work fell silent at the age of two years. She lost her ability to use her hands and would rarely make eye contact. She could not walk with ease and most strikingly, would wring her hands constantly, she said.
However, the techniques of genome sequencing have transformed diagnosis, allowing us to identify causes of so many disorders, said Professor Zoghbi, whose investigations have provided vital clues to the genetic and molecular mechanisms of other neurological disorders such as Spinocerebellar ataxia type 1 and Huntingtons disease.
We are at a time when we can contemplate therapies, she said, adding studies were under way to find out if an anti-epileptic drug can pharmacologically reverse some of the crippling symptoms. Years of research on mice models revealed that when MECP2 was not at its optimal level it impacted a specific class of neurons (GABAergic neurons), which could become targets for therapy to rescue MECP2 levels and therefore alleviate symptoms, she said.
Professor Zoghbi will deliver her lecture at the Music Academy in Chennai at 4.30 p.m., Wednesday, and at the Teen Murti Auditorium in New Delhi at 4.30 p.m. on Friday.
Read more:
Molecular geneticist Zoghbi throws light on enigmatic neurological disorder
Prof Philippos Patsalis speaks about Cyprus School of Molecular Medicine
Professor Philippos Patsalis, Chief Executive Director of the Cyprus School of Molecular Medicine speaks as a guest on the TV show Mazi sto RIK. Read more ab...
By: EducationscomTV
Read more:
Prof Philippos Patsalis speaks about Cyprus School of Molecular Medicine - Video
Cyprus Institute of Neurology and Genetics|Cyprus School of Molecular Medicine
Take a tour of the Cyprus School of Molecular Medicine. You can read more about CSMM and the institute #39;s degree programs here: http://www.educations.com/Cypr...
By: EducationscomTV
Read the rest here:
Cyprus Institute of Neurology and Genetics|Cyprus School of Molecular Medicine - Video
Exposing adolescent rats to THC (tetrahydrocannabinol) the primary psychoactive ingredient in marijuanacan lead to molecular and behavioral alterations in the next generation of offspring, even though progeny were not directly exposed to the drug, researchers at the Icahn School of Medicine at Mount Sinai have found.
Male offspring showed stronger motivation to self-administer heroin during their adulthood and molecular changes in the glutamatergic system, which is the most important excitatory pathway for neurotransmission in the brain. Damage in the glutamate pathway, which regulates synaptic plasticity, has been linked to disturbances in goal-directed behavior and habit formation.
The study is published online January 22 in Neuropsy-chopharmacology.
Our study emphasizes that cannabis (marijuana) affects not just those exposed, but has adverse affects on future generations, said Yasmin Hurd, PhD, the studys senior author, and professor of psychiatry and neuroscience at the Icahn School of Medicine at Mount Sinai. Finding increased vulnerability to drug addiction and compulsive behavior in generations not directly exposed is an important consideration for legislators considering legalizing marijuana.
In the study, Dr. Hurd and colleagues gave adolescent male rats 1.5 mg/kg of THC, similar to about one joint in human use. None of the rats had been exposed to THC before, but their parents were exposed to THC as teens and then mated later in life. THC-exposed offspring worked harder to self-administer heroin by pressing a lever multiple times to get heroin infusion.
Although marijuana use and safety tends to be discussed in terms of its impact to the individual during the lifetime, few studies have addressed adverse effects in future generations. What this opens up are many questions regarding the epigenetic mechanisms that mediate cross-generational brain effects, said Dr. Hurd.
Read more here:
In the quest for new treatments, U.S. researchers are looking to traditional Chinese medicines, some of the oldest remedies in the world.
A recent discovery resulted in a better treatment for a type of leukemia that strikes about 1 in 250,000 people in the U.S. Another study found a potential new painkiller in China's medicine chest. Other researchers are studying a traditional medicinal plant called "thunder god vine" for its anti-cancer properties.
The approach has already had some success. The Chinese herbal medicine artemisinin, for instance, has gone on to become the most potent anti-malarial drug available.
Not all the leads have panned out, of course. But the old field has shown enough potential to keep interest high.
A better leukemia treatment drawn from an ancient medicine should give us hope for developing anti-cancer drugs, says Dr. Samuel Waxman, a co-author of the report and professor of medicine and cancer specialist at Mount Sinai Hospital. "It gives a lot of optimism of seeking other types of cancer medicines in the Chinese pharmacopedia, which many people are looking into," Waxman says.
The treatment uses arsenic trioxide, which has traditionally been used in Chinese medicine. The U.S. Food and Drug Administration approved arsenic trioxide (sold as Trisenox here) as a treatment in 2000, and later research showed that patients who received standard chemotherapy followed by arsenic trioxide did better than patients who just received standard chemotherapy.
But a big clinical test recently found that the drug, in combination with all-trans retinoic acid another drug commonly used to treat acute promyelocytic leukemia (APL) turned out to be more effective than the usual chemotherapy.
That results means arsenic trioxide should become the new standard for patients that can use it, says Dr. Richard Stone, director of the adult acute leukemia program at the Dana-Farber Cancer Institute.
"So this was a cure for leukemia without chemotherapy, really for the first time in a large randomized trial," says Stone. "We've got a patient in the hospital right now who's receiving that very therapy."
He says there are still side effects from the new regimen affecting the skin and heart, but for most people they're less of a problem than the hair loss, vomiting and diarrhea that can come with chemotherapy.
See original here:
-- Research findings enable disease molecular sub-typing to lead to more informed clinical decision-making
IRVING, Texas, Jan. 18, 2014 /PRNewswire/ --Caris Life Sciences, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present a large international tumor profiling study of colorectal cancer (CRC) at the 2014 Gastrointestinal Cancers Symposium this week in San Francisco, Calif. With more than 7,000 patients comprehensively profiled by Caris Molecular Intelligence, this study represents the largest, multi-national analysis in a single laboratory setting of the main molecular anomalies in colorectal cancer. Colorectal cancer is the third most common cancer worldwide, with metastatic disease accounting for 40 to 50 percent of newly diagnosed patients.
"This comprehensive analysis of more than 7,000 patient cases illustrates that treatment of this cancer as one single disease is a flawed approach. The variety of mutations identified also point the way to new combinations of therapies and protein targets that can help direct future treatments," said Fadi Braiteh, M.D. and co-author on the study. "We are definitely moving from treating colon cancer as one disease to treating it as 20 to 30 different diseases. This research also highlights the feasibility of tumor profiling for colorectal cancer in the community setting, as well as establishes a high bar for standard of care for these patients."
This colorectal cancer study evaluated protein and DNA alterations in the EGFR pathway, including analysis of KRAS, NRAS, HRAS, BRAF, PIK3CA, ERBB4 and HER2 mutations/amplifications, as well as PTEN loss of expression and mutation in KRAS wild-type colorectal cancer patients. This dataset highlights the importance of the EGFR pathway in treating this disease by identifying a high frequency of specific and co-incident pathway alterations that have therapeutic implications.
"EGFR targeting therapies, cetuximab and panitumumab, are effective treatment for KRAS wild type CRC. Although mutations in KRAS predict resistance to EGFR Mab therapy, only 80 percent of CRC patients with KRAS wild type status respond to treatment," said Gargi Basu, Ph.D., from Caris Life Sciences and presenting author. "Testing for additional molecular alterations utilizing a multi-platform approach is critical to identifying those patients that are not likely to respond to anti-EGFR therapy alone and may respond better to a combination of targeted agents."
About Caris Molecular Intelligence
Caris Molecular Intelligence has been the leading cancer profiling service on the market since 2006, having been used for more than 60,000 cancer patients and counting by more than 6,000 oncologists in at least 59 countries to help develop individualized and actionable treatment plans that seek to improve patient care. Caris Molecular Intelligence utilizes the most comprehensive range of analytical technologies endorsed by the latest and most robust evidence immunohistochemistries, fluorescence and chromogenic in situ hybridization, polymerase chain reaction and Next-Generation sequencing to provide oncologists the most complete and clinically relevant profile of a patient's unique cancer-related biomarkers. Unlike other commercially available tumor profiling services, Caris Molecular Intelligence more completely interrogates a patient's unique tumor biology by going beyond just DNA analysis. Caris' service assesses additional important biological components like RNA and protein expression levels to establish a multi-dimensional profile of a patient's tumor that reveals more fully the complex biological processes that are driving that patient's cancer and, therefore, more, relevant targets for potential clinical action.
With a multi-dimensional profile of a patient's unique tumor, Caris Molecular Intelligence integrates insights from its proprietary and industry-leading evidence curation and bioinformatics platform to identify and report the most clinically relevant associations to drug therapies that are approved by the U.S. Food & Drug Administration or are in active clinical trials in the U.S. Managed by the Caris Evidence Design Board, a dedicated team of oncology experts that includes 5 Ph.D.s and 6 M.D.s, the Caris Molecular Intelligence evidence and bioinformatics platform curates, classifies and catalogues the findings and evidence from all relevant clinical studies in cancer and cancer biology available in the published scientific and medical literature, using a methodology adapted from the evidence review process of U.S. Preventive Services Task Force (www.uspreventiveservicestaskforce.org) of the Agency for Health Research and Quality (www.ahrq.gov). This platform incorporates the review of more than 100,000 publications and counting. Relying on the most robust evidence that meets Caris' quality standards, the Caris Molecular Intelligence evidence and bioinformatics platform can currently provide therapeutic guidance for up to 43 drug associations with Caris' multi-dimensional approach to tumor profiling, far exceeding the 12 that can be identified using next-generation sequencing alone. The Caris Molecular Intelligence bioinformatics platform electronically delivers the profile and all of these results in an easy-to-use report format that gives oncologists access to underlying evidence, enabling them to develop tailored treatment plans for each unique patient. For more information on Caris Molecular Intelligence, visit http://www.carismolecularintelligence.com.
About Caris Life Sciences
Caris Life Sciences is a leading biosciences company focused on fulfilling the promise of personalized medicine. As the first commercial mover in comprehensive molecular profiling in oncology, Caris Molecular Intelligence is an industry vanguard, with 60,000-plus patients profiled and counting. Ordered by nearly 6,000 oncologists in 59 countries, Molecular Intelligence correlates molecular data generated from a patient's tumor with biomarker/drug associations derived from clinical cancer literature. Using a variety of advanced and clinically-relevant technologies, Caris provides oncologists with the most clinically actionable information to help them personalize treatment for cancer patients. This multi-technology approach enables Caris to provide therapeutic guidance for 43 drug associations, compared to the 12 that can be found through use of next-generation sequencing alone. The company is also developing a series of blood tests based on its proprietary Carisome platform a revolutionary blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Australia and other international markets. To learn more, please visit http://www.carislifesciences.com.
Read the original post:
(PRWEB) January 17, 2014
The "Bioinformatics Market By Sector (Molecular Medicine, Agriculture, Research & Forensic), Segment (Sequencing Platforms, Knowledge Management Tools & Data Analysis Services) & Application (Genomics, Proteomics & Drug Design) Global Forecasts to 2017" analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia-Pacific and Rest of World.
Browse 120 market data tables with 22 figures spread through 364 pages and in-depth TOC on Bioinformatics Market" http://www.marketsandmarkets.com/Market-Reports/bioinformatics-39.html
Early buyers will receive 10% customization on this report.
Inquiry before buying at http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=1255.
This report studies the global bioinformatics market over the forecast period 2012-2017.
The global bioinformatics market was valued at $2.9 billion in 2012 and is poised to reach $7.5 billion by 2017 at a CAGR of 20.9%. Bioinformatics technologies are used in various pharmaceutical and biotechnology sectors to support their growth. Major sectors that use bioinformatics tools and services are medicine, agriculture, environment, animal, forensic, academics and others (home land security & defense, law-enforcement groups, bio-weapon creation, and evolutionary biotechnology). The medical sector accounted for the lions share of the bioinformatics market, owing to the increasing use of bioinformatics in the drug discovery and development process.
Product and services in the bioinformatics market comprise of platforms, knowledge management tools, and services. The bioinformatics platforms market is the fastest-growing segment, as they play a crucial role in quick and easy analysis and manipulation of large amounts of data obtained from NGS projects.
Applications of bioinformatics in life sciences research include genomics, proteomics, chemoinformatics, molecular phylogenetics, metabolomics, transcriptomics, and others (glycomics, cytomics, physiomics and interactomics). Genomics commands the largest share of the bioinformatics application market.
The decreasing cost of DNA sequencing, increasing funding from government and private organizations, and technical advancements in bioinformatics tools and platforms are propelling the market. Dearth of a common data format for integration of data, lack of well-defined standards, and shortage of skilled bioinformatics professionals are major hurdles to growth of the market. It is expected that the market will offer growth opportunities for bioinformatics solutions manufacturers with the introduction and adoption of upcoming technologies such as nanopore sequencing and cloud computing.
Read more:
Michael McDermott on the implications of inflammation.
Michael McDermott is Professor of Experimental Rheumatology at the Leeds Institute for Molecular Medicine, as well as a Faculty Member in the Rheumatology an...
By: Facultyof1000
Go here to see the original:
Michael McDermott on the implications of inflammation. - Video
Contact Information
Available for logged-in reporters only
Newswise A team of researchers from the Cleveland Clinic and Case Western Reserve School of Medicine have identified critical complex mechanisms involved in the metastasis of deadly triple negative breast cancers (TNBC). These tumors are extremely difficult to treat, frequently return after remission, and are the most aggressive form of breast cancer in women. The discovery of this critical interaction of mechanisms could be used to develop new life saving treatments to kill metastatic tumors in TNBC.
In previous findings published over the past 10 years, our teams have described key mechanisms in these critical proteins, said Khalid Sossey-Alaoui, PhD, Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic. A key component in the deadly metastatic potential of TNBC tumors is that they spread through tissues outside the breast very quickly. The two proteins that we studied, WAVE3 and TGF-, when together, promote tumor aggressiveness.
We found important biological implications, said William Schiemann, PhD, an associate professor, Division of General Medical Sciences-Oncology, Case Western Reserve School of Medicine, and co-leader of the Breast Cancer Program at the Case Comprehensive Cancer Center. For the first time, we uncovered an interplay between the two proteins that can inhibit or suppress TNBC a discovery that has the potential to inhibit proliferations of the tumor.
The next step in the research process is to find a way to deliver inhibitors to the tumor. Using nanoparticles, the Sossey-Alaoui, Schiemann team hope to deliver therapies directly to the site of the tumor and reverse the disease. Their goal is to move this basic research into clinical trials in the next three years.
This finding helps to uncover the complex cascade of events that lead to metastasis, said Stanton Gerson, MD, director of the Case Comprehensive Cancer Center and director of the Seidman Cancer Center at UH Case Medical Center. These studies are part of a broad initiative in breast cancer research through numerous collaborative efforts at the Case Comprehensive Cancer Center. Using a team science approach is the most efficient and productive way to have an impact in cancer.
Metastasis is a complex, multi-stage process in which primary tumor cells invade the surrounding cells, tissues and organs, integrate into blood vessels, and survive and move throughout the body. Metastasis of primary mammary tumors accounts for the vast majority of deaths of breast cancer patients. The five-year survival rate for patients with breast cancer drops precipitously from 98% for individuals with localized disease to 23% for those with metastatic disease.
Research support was provided in part by the National Institutes of Health to W.P.S. (CA129359) and E.F.P. (HL073311 and HL HL096062), and by the Department of Defense to K.S.-A. (BC073783) and to M.A.T.(BC093128). Additional support was provided to W.P.S. and K.S.-A. by pilot funds from the Case Comprehensive Cancer Center (P30 CA043703).
This study appeared in the print addition of Breast Cancer Research and Treatment on November 7, 2013. In addition to K. Sossey-Alaoui and W. P. Schiemann, co-authors on the paper include: M. A. Taylor, M. K. Wendt, Case Comprehensive Cancer Center; G. Davuluri, E. F. Plow, Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic; J. G. Parvani, Department of Pathology, Case Western Reserve University.
See original here:
Team Discovers Key Mechanisms to Inhibit Triple Negative Breast Cancers
Contact Information
Available for logged-in reporters only
Newswise LOS ANGELES (January 15, 2014) Investigators at the Cedars-Sinai Regenerative Medicine Institute have identified new molecular abnormalities in the diabetic cornea that could contribute to eye problems in affected patients. With this new knowledge, investigators aim to accelerate the process of healing and repair in damaged corneas to ultimately reverse the effects of diabetes-induced eye complications.
We observed small but significant changes in the gene expressions between normal and diabetic corneas, said Mehrnoosh Saghizadeh Ghiam, PhD, assistant professor of biomedical sciences and neurosurgery, a researcher in the Regenerative Medicine Institute Eye Program and the lead author of the study published in the journal PLOS ONE. These slight alterations may contribute to disease progression and cause cascading effects on the cellular functions that prevent wound healing and eventually contribute to vision impairment.
Diabetes is a systemic disease affecting all parts of the body, including the eye and may lead to vision loss. Roughly 50 to 70 percent of diabetic patients suffer from corneal complications that include alterations in vital corneal stem cells, causing lasting defects and eventually, vision impairment.
Investigators identified gene expression regulators, microRNAs, in normal and diabetic human corneas. They then successfully confirmed that several of these regulators were expressed differently in the diabetic corneas. These differently expressed microRNAs may contribute to stem cell and epithelial (tissue cells) abnormalities in diabetic corneas. Researchers are working on the manipulation of these microRNAs by gene therapy to normalize these corneas.
No previous studies have addressed the role of microRNAs in the corneas of patients with diabetes, said Alexander Ljubimov, PhD, director of the Eye Program at the Regenerative Medicine Institute and co-author of the paper. This first-of-a-kind study will allow researchers to better understand the roles of microRNAs in corneal diseases.
The study was conducted by a team of Cedars-Sinai researchers including Saghizadeh Ghiam, Ljubimov, Vincent Funari, PhD, director of the Cedars-Sinai Genomics Core in the Department of Biomedical Sciences, and research associates Michael Winkler and Jordan Brown.
The research was supported by the following National Institutes of Health (NIH) grants: NIH R21 EY022771 and R01 EY13431, as well as the Cedars-Sinai Regenerative Medicine Institute.
# # #
Read more from the original source:
Mon Jan 6, 2014 4:30pm EST
* Reuters is not responsible for the content in this press release.
Foundation Medicine Extends and Expands Collaboration to Provide Molecular Information and Genomic Profiling for Clinical Oncology Programs
Foundation Medicine today announced it has extended and expanded its ongoing collaboration with Novartis to provide molecular information and comprehensive genomic profiling analysis in support of many of Novartis clinical oncology programs. The collaboration will now extend through at least September 2016.
As the result of Foundation Medicine and Novartis pilot program established in January 2011 and an expanded three-year agreement in June 2012, Foundation Medicines comprehensive genomic profiling has generated clinically relevant data and is now regularly used in many of Novartis oncology clinical trials. This new agreement, which the companies agreed to extend and expand prior to the end of the existing term, includes committed capacity for Foundation Medicine to provide genomic profiling of patient samples from Novartis clinical trials, as well as access to Foundation Medicines molecular information and analysis services. The new three-year agreement also gives Novartis the option to extend the term for an additional two-year period. Financial terms are not being disclosed.
We are deeply committed to our relationship with Novartis and pleased with the continued growth of our collaboration, said Michael J. Pellini, M.D., president and CEO, Foundation Medicine. In addition to providing comprehensive genomic profiling for patients in Novartis clinical trials, this expanded agreement will allow Novartis to take advantage of our unique and growing database of molecular information to support the evaluation and development of Novartis oncology drug candidates, biological targets and clinical trials.
Foundation Medicine uses comprehensive, clinical grade next-generation sequencing to assess routine cancer specimens for all genes that are currently known to be somatically altered and unambiguous drivers of oncogenesis in solid tumors and hematologic malignancies, as well as many sarcomas and pediatric cancers. Novartis uses these capabilities to support its targeted therapy clinical development efforts by helping to align the genomic profile of individual patients cancer with clinical trial enrollment criteria and clinical outcome analysis.
About Foundation Medicine
Foundation Medicine (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patients unique cancer. The companys clinical assays, FoundationOneTM for solid tumors and FoundationOneTM Heme for hematologic malignancies, sarcomas and pediatric cancers, each provide a fully informative genomic profile to identify a patients individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicines molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine is a registered trademark, and FoundationOneTMis a trademark, of Foundation Medicine, Inc.
See original here:
Foundation Medicine Extends and Expands Collaboration to ...
UC San Francisco and Quest Diagnostics, the world's leading provider of diagnostic information services, have formed a collaboration to accelerate the translation of biomedical research into advanced diagnostics in the field of precision medicine, for improved patient care, treatment and outcomes.
Initial clinical areas of focus include autism, oncology, neurology and womens health.
The collaboration, which combines the research discoveries and capabilities of UCSF with the national testing database and technical and clinical development capability of Quest Diagnostics, has an overarching aim of enabling holistic and integrated diagnostic solutions that close gaps in care or enable new clinical value.
Under the terms of the agreement, scientists will jointly research, develop and validate diagnostic innovations to solve specific clinical problems and provide actionable information to improve patient care. The organizations will focus on diagnostics to advance precision medicine, an emerging field of medical science that aims to integrate the most informative data from molecular, clinical, population and other research to create predictive, preventive and precise medical solutions for patients. Quest Diagnostics would independently develop and validate any lab-developed tests for clinical use that emerge from the collaborations research.
Researchers will utilize laboratory-based diagnostics, imaging procedures and population analysis based on Quests national Health Trends database, the largest private clinical database in the U.S., based on more than 1.5 billion patient encounters, to advance precision medicine.
The alliance is the first master agreement that UCSFs Office of Innovation, Technology and Alliances has signed with a clinical laboratory testing company and augments the universitys efforts to translate laboratory research into new therapies. The broad agreement lays the groundwork for multiple projects between the two organizations.
Advances in technology and science have identified many promising opportunities to improve outcomes through insights revealed by novel diagnostic solutions, yet fulfilling the full potential of these opportunities often hinges on translational clinical studies which validate their value, said Jay Wohlgemuth, MD, senior vice president, Science and Innovation, Quest Diagnostics. This unique collaboration between UCSF and Quest brings together the finest researchers and clinicians in the country to accelerate the development of a product pipeline of scientific discoveries as clinically valuable diagnostic solutions that enable precision medicine for improved outcomes.
The collaboration is launching with two specific projects already underway. One project involves Quests national database of molecular testing data to facilitate participation in research and development efforts related to genetic variations of autism, based on Quests CGH microarray ClariSure technology, which can help identify genetic mutations associated with autism and other developmental disorders. While there currently is no treatment for autism, a test that aids its diagnosis could help identify individuals who might be appropriate candidates for research studies that could lead to future therapies.
The second project aims to identify biomarkers to determine which children with glioma brain tumors may benefit from a drug that is currently available to treat the disease. That project will integrate molecular biomarker testing with advanced MRI imaging technologies. This project is the first phase of larger collaborative studies to develop and validate integrated care pathways, which would include laboratory diagnostics, imaging data and other clinical information to be used in the management of patients with brain cancer and neurological diseases.
UCSF has been at the forefront of the movement toward precision medicine, for which UCSF Chancellor Susan Desmond-Hellmann, MD, MPH, co-authored the initial National Academy of Sciences paper that defined the new field. That paper set the vision of harnessing the vast amounts of genetic, environmental and health data worldwide to make health care more predictive, precise and targeted.
Continued here:
UCSF and Quest Diagnostics Launch Collaboration to Advance Field of Precision Medicine